Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News

ecancer sources relevant oncology news from key institutes, journals, governments, NGOs and charities, along with commissioned pieces from our dedicated news team.

Terahertz polarimetry detects microscopic tissue changes linked to cancer and burns

Terahertz polarimetry detects microscopic tissue changes linked to cancer and burns

A study led by CIC bioGUNE delves into the complexity of the most aggressive form of prostate cancer

A study led by CIC bioGUNE delves into the complexity of the most aggressive form of prostate cancer

Genomic abnormalities in T-follicular helper lymphoma and patient outcomes

Genomic abnormalities in T-follicular helper lymphoma and patient outcomes

Pancreatic cancer spreads to liver or lung thanks to this protein

Pancreatic cancer spreads to liver or lung thanks to this protein

ASCO 2025: Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study of antibody-drug conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

ASCO 2025: Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study...

FDA approves darolutamide for metastatic castration-sensitive prostate cancer

FDA approves darolutamide for metastatic castration-sensitive prostate cancer

Loss of Y chromosome leads to poor cancer outcomes

Loss of Y chromosome leads to poor cancer outcomes

Bioactive soluble recombinant mouse LIGHT protein promotes effective tumour immune cell infiltration delaying tumour growth

Bioactive soluble recombinant mouse LIGHT protein promotes effective tumour immune cell infiltration delaying...

ASCO 2025: Adding niraparib to standard treatment may slow cancer growth for some patients with mCSPC

ASCO 2025: Adding niraparib to standard treatment may slow cancer growth for some patients with mCSPC

ASCO 2025: Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers

ASCO 2025: Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast...

More from ecancer